By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



Corporate Headquarters
One Amgen Center Drive
Thousand Oaks  California  91320-1789  U.S.A.
Phone: 805-447-1000 Fax: 805-447-1010


Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

For more information, visit, LinkedIn and follow us on


Key Statistics

Ownership: Public

Web Site: Amgen
Employees: 20,000
Symbol: AMGN

Company News
Amgen (AMGN) Enters Into Agreement With Inovalon And Avalere To Engage Value-Based Contracting Opportunities 3/29/2017 9:07:05 AM
Nearly 500 Amgen (AMGN) Staffers to be Reassigned, Relocated or Laid Off in Restructuring 3/26/2017 8:30:24 PM
How This New Jersey Biotech is Taking on Amgen (AMGN) 3/24/2017 7:00:23 AM
Amgen (AMGN) Release: European Commission (EC) Approves Amgevita (Biosimilar Adalimumab) For The Treatment Of Certain Inflammatory Diseases 3/24/2017 6:50:54 AM
Drug Giant Amgen (AMGN) to Create Hundreds of New Jobs in Florida 3/23/2017 5:28:16 AM
UCSF Heart Doctor Wary of Amgen (AMGN)-Paid Repatha Study 3/22/2017 6:34:03 AM
Amgen (AMGN) Release: Analyses Of Pcsk9 Inhibitor Prescription Rejection Rates Demonstrate Significant Access Barriers For Appropriate Patients 3/20/2017 10:35:33 AM
Disappointment Hits as Amgen (AMGN)'s Repatha Prevents Heart Attacks, But Not Deaths 3/17/2017 7:37:55 AM
Amgen (AMGN) Release: Repatha (Evolocumab) Four-Year Open-Label Follow-Up Study Published In 'JAMA Cardiology' 3/15/2017 6:33:54 AM
Amgen (AMGN) Release: Repatha (Evolocumab) Demonstrates Reduced Need For Apheresis In Patients With High LDL Cholesterol In Phase III Study 3/13/2017 7:15:39 AM